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The purpose of this study was to ascertain the optimal pharmacokinetic model for milrinone in
pediatric patients after cardiac surgery when milrinone was administered as a slow loading dose
followed by a constant-rate infusion. The data used for pharmacokinetic analysis were collected
in a prospective, randomized, placebo-controlled multi-center trial of milrinone as prophylaxis
for the development of low cardiac output syndrome after surgery for repair of complex congen-
ital cardiac defects. Two blood samples were randomly collected from each patient for determi-
nation of plasma milrinone concentrations with subsequent population pharmacokinetic
modeling. The pharmacokinetics of milrinone in pediatric patients under 6 year’s age were best
described by a weight-normalized one compartment model after a slow loading dose followed by
a constant-rate infusion. The volume of distribution was 482 ml kg)1, and was independent of
age. Clearance was a linear function of age given by Cl ¼ 2.42 ml kg)1 min)1[1+0.0396*age].
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INTRODUCTION
More than 300,000 children under the age of 21 have congenital
cardiovascular disease, and 38% will undergo at least one surgical pro-
cedure. Advances in cardiac surgery have increasingly made repair early
in life more feasible. However, even with advances, there is a predict-
able and reproducible decrease in cardiac output, low cardiac output
syndrome (LCOS), after cardiac surgery (1–3). LCOS occurs even if
there are no residual cardiac lesions. The causes of LCOS are multi-
factorial and include myocardial ischemia due to aortic cross-clamping,
the residual effects of cardioplegia, and activation of inflammatory
pathways from exposure of blood to foreign surfaces during cardiopul-
monary bypass (CPB). LCOS is associated with increased mortality and
morbidity and is seldom left untreated (1,2). Standard therapy for
LCOS has included catecholamines, but catecholamines may exacerbate
tachycardia and the risk of dysrhythmias, and may increase afterload.
Because of these adverse effects, the phosphodiesterase inhibitors are
being increasingly used for the treatment of LCOS. Rational use of
any drug requires an understanding of the drug’s pharmacokinetics.
While the pharmacokinetics of the phosphodiesterase inhibitor, milri-
none, has been described in two studies, the numbers of patients in
both studies were small (4,5).
Furthermore, pharmacokinetic models are often a reflection of how
the drug is dosed and the previous studies were initiated in the operat-
ing room with loading doses of the study drug. The pharmacokinetics
of milrinone, in pediatric patients after biventricular repair, is discussed
in this report. This analysis is based on data derived from a multi-cen-
ter randomized double-blind study of milrinone for the prevention of
LCOS in pediatric patients after cardiac surgery, the PRIMACORP
study (6,7). The objectives of this analysis were (1) to determine the
best population pharmacokinetic model for milrinone in pediatric
patients using the study dose regimen and (2) to determine whether the
covariates of weight, age, hepatic function, and renal function, influ-
enced drug disposition. Patients in this study were randomly adminis-
tered either placebo, low-dose milrinone, or highdose milrinone, as
described below, and followed for 36 hr. During this period blood sam-
ples were taken randomly from each patient for determination of milri-
none plasma concentration. The number of blood samples was limited
to two per patient and, consequently, population pharmacokinetic
methods were used for the analysis.
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METHODS
The PRIMACORP trial was a randomized double-blind multi-center
trial of milrinone as prophylaxis for the development of LCOS (6,7). The
Institutional Review Boards of each of the participating institutions
approved the protocol and informed consent. A total of 242 patients in
31 institutions were enrolled after obtaining informed consent from par-
ents or guardians.
The protocol stipulated the administration of placebo or one of two
doses of milrinone, in a randomized, double-blind manner, to pediatric
patients at high risk of developing LCOS after cardiac surgery. The inclu-
sion criteria stipulated patients 6 years or younger who required surgery
for anatomic repair of certain congential defects: transposition of the great
arteries with or without a ventricular septal defect (VSD), VSD with an
arch anomaly, complete atrioventricular canal, tetralogy of Fallot, total
anomalous pulmonary venous repair, truncus arteriosus, double-outlet
right ventricle (biventricular repair), anomalous left coronary from the pul-
monary artery, and congenital mitral or aortic valve defects. Eligible
patients who were deemed stable and not experiencing LCOS were enrolled
within 90 min after arrival in the intensive care unit. Enrolled patients were
randomized to either placebo, low dose milrinone (25 lg kg)1 over 60 min
followed by a 0.25 lg kg)1 min)1 infusion) or high dose (75 lg kg)1 over
60 min followed by a 0.75 lg kg)1 min)1 infusion). Milrinone was contin-
ued for up to 36 hr during which time patients were evaluated for the pri-
mary endpoint of the study, a composite of death or the development of
LCOS, requiring one or more of the following: (1) initiation of mechanical
support of the circulation, (2) administration of new, open-label positive
inotropic agents or other pharmacological support, or (3) an increased
need (‡100% over baseline) for existing pharmacological support. Patients
were diagnosed with LCOS if they demonstrated clinical signs of the syn-
drome-tachycardia, oliguria, cold extremities or cardiac arrest-with or
without a ‡30% difference in arterial-mixed venous oxygen saturation or
metabolic acidosis (an increase in the base deficit of >4 or an increase in
lactate of >2 mg dl)1) on two successive blood gas measurements. Study
drug (placebo or milrinone) was discontinued when LCOS was diagnosed.
Two blood samples were drawn from each patient for determination
of milrinone plasma concentrations. The sampling times were randomly
selected from the following schedule: 15, 30, 45, 60, 90, 120, 180, 240,
360, or 480 min after initiating study drug, with the proviso that samples
were at least 2 hr apart in any one patient. If the primary endpoint was
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reached, study drug was stopped and a sample was obtained at that time
point if two previous samples were not already obtained. These samples
provided the data base for the pharmacokinetic analysis. Other data col-
lected for the pharmacokinetic analysis included the following informa-
tion: study site, patient identification number, sampling times, study drug
concentration, infusion pump rates, infusion duration, and the covariates
weight, age, aspartate aminotransferase (AST), alanine aminotransferase
(ALT), creatinine clearance (CrCl), development of LCOS, and presence
of serious adverse event (SAE).
Blood samples were collected into vacutainer tubes containing sodium
heparin. Tubes were inverted 10–15 times to assure mixing and then were
centrifuged for 15 min at 3500 rpm. Plasma was separated and transferred
to pre-labeled plastic storage tubes. Samples were frozen and shipped to Co-
vance Laboratories (Indianapolis, IN) for temporary storage until shipment
to Emory University. Samples were shipped frozen, on dry ice overnight, to
Emory University in Atlanta, Ga. Upon arrival, samples were inspected
and immediately placed in a )70 C freezer and kept frozen until analysis
time. A high performance liquid chromatographic (HPLC) validated
method was used for the determination of milrinone in human plasma (8).
For the analysis, samples were thawed at room temperature, and aliquots
of patients’ samples were mixed with internal standard (IS-SW041417), and
after addition of ammonium sulfate, were extracted into ethyl acetate and
back-extracted into 0.1 N hydrochloric acid. Traces of ethyl acetate were
removed at 45 C under nitrogen and after pH adjustment, samples were
chromatographed on a C18 column at 25 C using mobile phase consisting
of a mixture of phosphate buffer and acetonitrile. Detection of milrinone
and the internal standard was achieved by UV detection at 340 nm. Signals
from the detector were collected and stored on a Vectra VL computer
equipped with Chem Station software (part of the HPLC system).
The relationship between peak area ratio (drug/IS) and amount ratio
(drug/IS) was found to be linear within 5–500 ng ml)1 for milrinone in
plasma with an average correlation coefficient of 0.999. Inter-day precision
of the method ranged from 9.54% at 5 ng ml)1 to 4.24% at 500 ng ml)1
and accuracy of the method ranged from 98% to 104%. The limit of
quantitation (LOQ) from 1 ml of plasma was 5 ng ml)1.
Because there were, at most, two samples for each patient, the data
were analyzed using population pharmacokinetic methods. This was done
using NONMEM, Version 5 (9). One, two, and three compartment models
were considered, assuming intravenous dosing into a central compartment.
The pharmacokinetic parameters were the compartment volumes, elimina-
tion clearance, and inter-compartmental distribution clearances. We
assumed that each structural parameter had a log normal distribution, i.e.,
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Pi ¼ Ptv expðgiÞ
where Pi is the parameter for individual i, Ptv is the ‘‘typical value’’ for
the population, and gi is a random variable from a distribution with a
mean of zero and variance denoted by hg2i. We considered models in
which the g values for different parameters (volumes and clearances) could
be correlated, as well as models in which we assumed that different
parameters were not correlated. We assumed that the residual error, the
difference between predicted and measured milrinone concentrations,
could be described by a log normal plus additive model, i.e.,
Cm ¼ Cp þ Cp expð1Þ þ e2
where Cm is the measured concentration, Cp is the predicted concentra-
tion, and e1 and e2 have normal distributions with means of zero.
NONMEM estimates pharmacokinetic parameters by determining
the parameter values that minimize the ‘‘objective function’’, which is
minus two times the logarithm of the likelihood of the observed results
(9). In general, the integrals needed to evaluate the objective function are
too complicated to solve without approximation. In the first order estima-
tion approximation, the log likelihood is expanded to first order around
the mean values of the gs (which are zero by assumption), simplifying the
objective function (9,10). In the conditional estimation techniques, it is
recognized that expansion around g=0 may be a poor approximation
and, instead, the log likelihood is expanded to first order around condi-
tional estimates of the g, derived from the prior iteration (9,10). We used
the first order estimation technique for initial model building. This is in
line with the recommendations of the NONMEM Project Group (9).
However, final models were compared using the first order conditional
estimation technique.
The optimal compartment model was selected using the Aikake Infor-
mation Criterion (9), which stipulates that the optimal model is that
which minimizes the sum of the objective function plus two time the total
number of parameters. We compared one, two, and three compartment
models without inclusion of weight as a covariate. However, it was recog-
nized that weight may be an important pharmacokinetic covariate in a
pediatric population and that clinicians dose drugs on a per kilogram
basis. Consequently, it was considered impossible to select an optimal
compartment model without consideration of body mass. Therefore, com-
parisons were made of one, two, and three compartment models in which
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it was assumed that each parameter was directly proportional to body
weight, i.e., we assumed that P ¼ Q*W, where Pi is the pharmacokinetic
parameter (compartment volume or clearance), Q is estimated, and W is
weight. We also considered a more sophisticated method of incorporating
weight as a covariate, in which both volumes and clearance were assumed
to be given by P ¼ Q1*WQ2 where both Q1 and Q2 are estimated. The
optimal compartment model was identified by the Aikake Information
Criterion for both weight-corrected and weight-independent models.
Following identification of the optimal compartment model (includ-
ing weight-dependence), the conditional (non-Laplace) estimation method
was used to estimate g values for individual patients for each parameter.
These were plotted vs. the covariates age, AST, ALT, CRT. These plots
were evaluated for significant correlations between g (which is a measure
of the deviation of the patient’s pharmacokinetic parameter from the
‘‘typical value’’) and the covariate in question, for further development of
the model. For both clearance and volume of distribution, a two-tailed
t-test (assuming equal variances) was used to compare estimates in
patients with and without LCOS and to compare estimates in patients
with and without SAEs.
RESULTS
The data set was comprised of 462 plasma samples collected from
235 patients at 29 clinical sites. There were 78 patients each in the placebo
and high dose groups and 79 patients in the low dose group. There were
46 neonates (0–1 month), 93 infants (1–24 months), and 18 children
(>24 months) who received either the high or low dose. The mean age of
patients receiving milrinone was 7.2 months and the mean weight was
5.8 kg. The three most common operations were repair of tetralogy of
Fallot (n ¼ 54), repair of complete atrioventricular canal defects (n ¼ 45),
and the arterial switch procedure (n ¼ 36). Figure 1 is a histogram of the
sampling times. Figure 2 is a plot of the observed milrinone concentra-
tions as a function of time.
The various pharmacokinetic models considered are described in
Table I, which also summarizes the results of non-linear regression func-
tion for the model. Model identification was begun by considering the
simplest, a one compartment model, and comparing models in which the
parameters (volume of distribution and clearance) were independent of
weight and in which the parameters were directly proportional to weight.
Assuming that volume of distribution and clearance were directly propor-
tional to weight (and ignoring interparameter correlation) resulted in a
significant decrease of the objective function from 2835 to 2660.
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Minimization of the objective function for a two compartment model
in which parameters were independent of weight and which assumed no
correlation between parameters terminated in a rounding error with a
value of 2840. Assuming that the parameters were directly proportional
to weight led to a significantly improved objective function of 2667.
Fig. 1. A histogram of sampling times.
Fig. 2. Measured milrinone concentration as a function of time. The solid line is a LOESS
smoother.
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The three compartment model failed to converge with or without normali-
zation of parameters by weight due to rounding errors, although the
objective function at the point of termination was significantly lower
(2667 vs. 2840) for the weight-normalized model. Because the assumption
of weight-proportional parameters significantly improved the objective
function for both one and two compartment models, this assumption was
utilized in further model identification.
Since the three compartment weight-normalized model failed to con-
verge due to rounding errors with an objective function no lower than the
two compartment model, it was not given further consideration. Weight-
normalized one and two compartment models were further investigated.
The objective function for the weight-normalized one compartment
model was 2660 while the objective function for the weight-normalized
Table I. Model Development
Data Set Model Results of regression
Full 1 compartment, no weight correction obj = 2835
Full 1 compartment, P=Q*W obj = 2660
Full 2 compartment, no weight correction obj = 2840
Full 2 compartment, P=Q*W obj = 2667
Full 3 compartment, no weight correction obj = 2840 re
Full 3 compartment, P=Q*W obj = 2667 re
High dose 1 compartment, P=Q*W obj = 1441
High dose 2 compartment, P=Q*W obj = 1441
Low dose 1 compartment, P=Q*W obj = 1196
Low dose 2 compartment, P=Q*W obj = 1195
Neonates 1 compartment, P=Q*W obj = 808
Neonates 2 compartment, P=Q*W obj = 812
Infants 1 compartment, P=Q*W obj = 1600
Infants 2 compartment, P=Q*W obj = 1602
Children 1 compartment, P=Q*W obj = 944
Children 2 compartment, P=Q*W obj = 943
Full 1 compartment, P=Q*W, CE obj = 2636
Full 1 compartment, P=Q*W/age-corrected, CE obj = 2616
Full 1 compartment, P = Q1*WQ2/age-corrected, CE obj = 2619
Data set refers to patients used for the analysis, with stratification on the basis of dose and
age group (neonate 0–1 month, infant 1–24 months, children>24 months). Regression results
are expressed in terms of the objective function (obj) with a lower value indicating a superior
fit. The model with the smallest Aikake information criterion was chosen as the superior
model. Note that the objective function is smaller for smaller data sets. P = Q*W indicates
that each pharmacokinetic parameter is assumed to be directly proportional to weight. Age
correction indicates that clearance is assumed to be a linear function of age, as discussed in
the text. P = Q1*WQ2 indicates that we allowed pharmacokinetic parameters to be propor-
tional to weight raised to variable powers, estimated by NONMEM. CE denotes first order
conditional estimation.
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two compartment model was 2667, using the first order estimation
technique. This indicated that the one compartment model is preferable.
Furthermore, the median absolute prediction error for both models was
essentially identical (0.39 to two significant digits) and the two models
were almost functionally identical. The estimate of volume of distribution
was 481 ml kg)1 for the one compartment model and 528 ml kg)1 for
the two compartment model (V1 ¼ 174 ml kg)1, V2 ¼ 354 ml kg)1). The
estimate of elimination clearance was 3.00 ml kg)1 min)1 for the one
compartment model and 3.04 for the two. More importantly, the
estimate of distribution clearance for the two compartment model
was 102 ml kg)1 min)1, indicating very rapid distribution into the total
volume of distribution and functional equivalence to a one compartment
model.
The one and two compartment models were compared for several
patient subgroups. When stratified by age, neonates (1 month or less),
infants (1 month to 2 years) and children (age 2–6 years), the one compart-
ment model was superior to the two compartment model in each age group.
As observed for the full data set, in neonates and infants the two compart-
ment model was functionally equivalent to a one compartment model due
to very rapid distribution clearances (Q ¼ 103 and 226 ml kg)1 min)1
respectively). In children, the parameter estimates for the two compart-
ment model were functionally distinct from the one compartment
model (V1 ¼ 166 ml kg)1, V2 ¼ 269 ml kg)1, Cl ¼ 6.29 ml kg)1 min)1, Q ¼
4.75 ml kg)1 min)1). However, the objective functions were virtually identi-
cal. We also considered the possibility that dose influenced the optimal
model. The two dose groups were analyzed separately. Again, the one com-
partment model was optimal.
In summary, the weight-normalized two compartment model did not
significantly improve the quality of the fit, the predictive accuracy was no
different and it was no different functionally than the one compartment
model. Furthermore, the one compartment model was superior in each of
the patient age subgroups. The weight-normalized one compartment
model was adopted for further analysis.
Using the weight-normalized one compartment model, values of g for
individual patients (the deviation of the estimate of either clearance or
volume of distribution for the individual patient from the mean) were esti-
mated using the first order conditional estimation technique. The esti-
mates were plotted vs. the covariates of age, ALT, AST, and CrCl. There
were no significant correlations between either g and AST, ALT, or CrCl.
There were significant correlations between age and individual g values
for Cl. This is illustrated in Fig. 3. There was no correlation between g
values for Vd and age.
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Since the g value for clearance was correlated with age, a model was
considered in which clearance was modeled as a linear function of age,
i.e.,
Cl ¼ Hð1Þ Weight  ½1þHð2Þ Age
in which Q(1) is the baseline clearance for a newborn and Q(2) represents
the increment in clearance with increasing age. This improved the objec-
tive function by 20 units when first order conditional estimation was used.
The estimates of Q(1) and Q(2) (with standard error in parentheses) were
2.42(0.288) and 0.0396(0.0139).
We also considered the possibility that the relationship between phar-
macokinetic parameters and weight was more complex than simple direct
proportionality. However, a model that allowed both volume of distribu-
tion and clearance to be proportional to variable powers of weight actu-
ally resulted in a slight increase in the objective function despite the
addition of two parameters and was not given further consideration.
Cl was lower in those patients having SAE (mean g value of–0.11)
compared to those who did not (mean g of 0.05), using a two-tailed t-test
assuming equal variances (p ¼ 0.038) (Fig. 4). The individual values of Vd
tended to be lower in patients who experienced a SAE (mean g of )0.12)
than in patients who did not (mean g of 0.035) but this was not significant
Fig. 3. Values of gCl vs. age where gCl is the deviation of the estimate of clearance for an
individual from the mean estimate. The solid line is a LOESS smoother.
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(p ¼ 0.084). The individual values of Cl tended to be lower in patients
who experienced LCOS (mean g of )0.12) compared to those who did not
(mean g of 0.03), but it was not significant at the 0.05 level (p ¼ 0.081)
(Fig. 5).
Fig. 4. Individual clearance values for patients who experienced a SAE vs. those who did
not.
Fig. 5. Individual clearance values for patients who experienced LCOS vs. those who did
not.
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The weight-normalized one compartment model with clearance as a
linear function of age was adopted as the final model for the total patient
population. The volume of distribution was 482 ml kg)1 and clearance
was given by the relationship
Cl ¼ 2:42mlmin1kg1ð1þ 0:0396ageÞ
A plot of measured concentration vs. the predicted concentration without
post hoc conditional estimation (denoted PRED) for this model is shown
as Fig. 6. Figure 7 presents measured concentration vs. predicted concen-
tration with conditional estimates (denoted IPRED). Figure 8 shows the
ratio, Cm/Cp (PRED), as function of time. Figure 9 presents weighted
residuals (WRES) as a function of time.
Table II presents parameter estimates (with standard errors) for the
final model as well as estimates for the following patient subgroups: neo-
nates, infants, children, patients receiving the high dose and patients
receiving the low dose. It should be noted that when the patients are strat-
ified by age the estimates of clearance increase with age.
DISCUSSION
The primary finding of this study was that the optimal pharmacoki-
netic model is a single compartment. The data were quite ‘‘noisy’’ with an
Fig. 6. The relationship between the milrinone concentration predicted by the final model
without using conditional estimation (PRED) and the measured concentration (Cm).
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absolute median prediction error of 0.39. The estimates of volume of dis-
tribution and clearance are not remarkably different from previously
reported values in pediatric patients. However, the two previous studies of
milrinone used two and three compartment models (4,5). There are
Fig. 7. The relationship between the milrinone concentration predicted by the final model
using conditional estimation (IPRED) and the measured concentration (Cm).
Fig. 8. The ratio of measured concentration, Cm, to predicted concentration, Cp (without
conditional estimation), as function of time. The solid line is a LOESS smoother.
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certainly differences between these earlier studies and the current one. The
prior studies enrolled far fewer patients and had older age distributions.
The current study is the only study of the pharmacokinetics of milrinone
that enrolled large numbers of neonates. This difference in typical patient
age may explain why the one compartment model was optimal in the cur-
rent study. However, much more plausible explanations are the dosing
schedule and the sampling schedule. The pharmacokinetic component of
the PRIMACORP trial was an ‘‘add-on’’ study, and the primary objective
of the trial was to determine whether milrinone was an effective prophy-
laxis for development of LCOS (6,7). Because of safety concerns in this
prophylaxis trial, it was deemed essential for patient enrollment and suc-
cessful completion of the study to give the loading dose over 1 hr. In con-
trast, in the prior pharmacokinetic studies of milrinone the loading doses
were given much more quickly. It is notable that the study that identified
a three compartment model (5) as optimal gave the loading dose over
5 min and the study which identified a two compartment model as opti-
mal gave the initial loading dose over 10 min (4). It is believed that when
the loading dose is given over 60 min, distribution processes are no longer
the rate-limiting step for equilibration of drug among body stores.
Instead, the infusion rate is the rate-limiting factor for drug disposition.
This makes it impossible to analyze the kinetics of distribution processes.
Furthermore, and most significantly for model development, only two
samples were taken from each patient. This was necessitated by the age
Fig. 9. Weighted residuals (WRES) as a function of time. The solid line is a LOESS
smoother.
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distribution of our study population and the ‘‘add-on’’ aspect of this
multi-center trial. Since multiple blood samples were needed for the evalu-
ation of the clinical end-point and since most of the patients were infants
or neonates, extensive sampling for pharmacokinetic purposes would have
been unethical. We elected to use random sampling times. We are una-
ware of any evidence that this leads to excessive bias and it is certainly
preferable to using the same fixed sampling schedule in every patient.
Given the sparse data available to us, the latter strategy would have had
no chance of identifying multiple compartments.
It should be noted that, given the positive clinical outcome of the
trial (7), the dosing schedule used for the study is likely to be adopted by
practitioners, and the pharmacokinetic model reported herein will be rele-
vant to how the drug is likely to be given.
As would be expected, we found that both volume of distribution
and clearance increased with increasing body weight. In our final model,
both volume of distribution and clearance were directly proportional to
weight. A weight-proportional model certainly simplifies dosing recom-
mendations for the clinician. However, there are plausible theoretical rea-
sons to believe that while volume of distribution may be directly
proportional to weight, clearance should be proportional to weight raised
to a power of 0.7 (11). Despite these theoretical considerations, a model
in which both parameters were proportional to a variable power of weight
did not improve the quality of the fit and was not further explored.
The most notable finding from this analysis of the influence of covari-
ates is that clearance, but not volume of distribution, increases linearly
with patient age. This suggests that the metabolic processes that eliminate
milrinone are functions of age. This could reflect a delayed maturation of
drug clearance processes. The clearance of milrinone in neonates was less
Table II. Estimates of Pharmacokinetic Parameters for the One Compartment Weight-
Corrected Model
Vd (ml kg)1) Cl (ml kg)1 min)1)
Group
Total (n = 157) 482 (39.3) 2.42(0.228)*[1+age*0.0396(0.0139)]
High (n = 78) 466 (17.1) 2.21(0.184)*[1+age*0.0379(0.0166)]
Low (n = 79) 505 (57) 2.55(0.396)*[1+age*0.0491(0.032)]
Neonates (0–1 m) (n = 48) 523 (28.5) 1.64 (0.373)
Infants (1–24 m) (n = 94) 461 (40.2) 3.38 (0.2)
Children (24–72 m) (n = 12) 353 6.68
Parameter estimates with standard errors in parentheses are shown. The covariance step was
unsuccessful for children so standard errors are not shown for this group. Use of age as a
covariate on Cl was not used for age-stratified groups (neonates, infants, children).
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than 25% of that in children, when analyzed by age stratification. This
indicates that a constant-rate infusion will take much longer to approach
steady-state levels in neonates. However, for the same infusion rate, the
steady-state concentration will be higher in neonates than older patients.
The clinical significance of this will obviously depend on the relative phar-
macodynamics of milrinone in different age groups. For example, consider
a 1 day old neonate and a 4 year old child. It is very easy to demonstrate
by simulation that if therapy is initiated with a constant-rate infusion of
0.75 lg kg)1 min)1, the plasma levels will always be higher in the neonate,
although it will take far longer to approach the steady-state concentration
in the neonate. The neonate will take 2 hr to reach 50% of the steady-
state concentration in comparison to 45 min for the older child. Use of a
loading dose infusion, as utilized in this study, reduces the time to
approach steady-state significantly (the time needed to reach 50% of
steady-state is now only 70 min for the neonate). If the pharmacodynam-
ics of milrinone is similar in the various age groups we can anticipate that
the onset of effect will be very similar in each group but the infusion rate
may need reduction in younger patients.
No relationship was found between either pharmacokinetic parameter
and hepatic function (as measured by AST and ALT) or renal function
(as measured by creatinine clearance).
Patients who had a SAE had significantly lower values of clearance
and a trend toward lower volumes of distribution. Patients who experi-
enced LCOS had a trend toward lower values of clearance. The clinical
significance of this is quite unclear, although clearance is an exposure
measure and lower values imply greater drug exposure.
In conclusion, the results of this study have clinical implications for
the pediatric intensivist using milrinone. The decrease in clearance with
age implies that a constant-rate infusion will eventually result in higher
blood levels in younger patients. However, the longer half-life of milri-
none in younger patients also implies that it will take longer to approach
steady-state, underscoring the necessity of a loading dose for the rapid
achievement of a therapeutic blood concentration. The intensivist should
also be aware that with longer duration of administration, dose reductions
may be appropriate and can be done without lowering the plasma concen-
tration below therapeutic levels.
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